Cargando…
Salivary, serological, and cellular immune response to the CoronaVac vaccine in health care workers with or without previous COVID-19
We investigated the anti-SARS-CoV-2 post-vaccine response through serum and salivary antibodies, serum antibody neutralizing activity and cellular immune response in samples from health care workers who were immunized with two doses of an inactivated virus-based vaccine (CoronaVac) who had or did no...
Autores principales: | Ortega, Marina Mazzilli, da Silva, Laís Teodoro, Candido, Érika Donizetti, Zheng, Yingying, Tiyo, Bruna Tiaki, Ferreira, Arthur Eduardo Fernandes, Corrêa-Silva, Simone, Scagion, Guilherme Pereira, Leal, Fabyano Bruno, Chalup, Vanessa Nascimento, Valério, Camila Araújo, Schmitz, Gabriela Justamante Händel, Ceneviva, Carina, Corá, Aline Pivetta, de Almeida, Alexandre, Durigon, Edison Luiz, Oliveira, Danielle Bruna Leal, Palmeira, Patricia, da Silva Duarte, Alberto José, Carneiro-Sampaio, Magda, Oshiro, Telma Miyuki |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9202665/ https://www.ncbi.nlm.nih.gov/pubmed/35710573 http://dx.doi.org/10.1038/s41598-022-14283-x |
Ejemplares similares
-
Patient with agammaglobulinemia produces anti-SARS-CoV-2 reactive T-cells after CoronaVac vaccine
por: Oshiro, Telma Miyuki, et al.
Publicado: (2022) -
Prevalence of anti-SARS-CoV-2 antibodies in outpatients of a large public university hospital in Sao Paulo, Brazil
por: Oliveira, Luanda Mara da Silva, et al.
Publicado: (2020) -
SARS-CoV-2 recombinant proteins stimulate distinct cellular and humoral immune response profiles in samples from COVID-19 convalescent patients
por: da Silva, Laís Teodoro, et al.
Publicado: (2021) -
Boosting immunity after CoronaVac
por: Sester, Martina, et al.
Publicado: (2022) -
Safety and immunogenicity of CoronaVac in people living with HIV: a prospective cohort study
por: Netto, Lucas C, et al.
Publicado: (2022)